US: AOLS - Aeolus Pharmaceuticl

六个月盈利: 0%
股息率: 0.00%

促销时间表 Aeolus Pharmaceuticl


关于公司 Aeolus Pharmaceuticl

Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology.

更多详情
Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents. The company is also developing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, as well as AEOL 20415 for treating infectious diseases. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.

IPO date 1996-02-01
ISIN US00765G1094
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.aeoluspharma.com
Цена ао 0.0001
每日价格变化: 0% (0.0001)
每周价格变化: 0% (0.0001)
每月价格变化: -66.67% (0.0003)
3个月内价格变化: -66.67% (0.0003)
六个月内的价格变化: 0% (0.0001)
每年价格变化: 0% (0.0001)
3年内价格变化: -87.5% (0.0008)
5年内价格变化: -91.67% (0.0012)
10年价格变化: 0% (0.0001)
年初以来价格变化: -66.67% (0.0003)

低估

姓名 意义 年级
P/S 0 0
P/BV 0 0
P/E 0 0
EV/EBITDA 0 0
全部的: 2.5

效率

姓名 意义 年级
ROA, % 0 0
ROE, % 0 0
全部的: 0

股息

姓名 意义 年级
Div yield, % 0 0
DSI 0 0
全部的: 0

责任

姓名 意义 年级
Debt/EBITDA 0 10
全部的: 10

成长冲动

姓名 意义 年级
盈利能力 Revenue, % -71.53 0
盈利能力 Ebitda, % -49.12 0
盈利能力 EPS, % -67.11 0
全部的: 2

导师 职称 支付 出生年份
Mr. John L. Mcmanus Chief Executive Officer and President 1964 (61 年)
Mr. Christopher Stanley Vice President of Operations

地址: United States, Mission Viejo, 26361 Crown Valley Parkway - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://www.aeoluspharma.com